Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Traws Pharma, Inc. Common Stock

TRAW

Traws Pharma Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It is advancing novel investigational antiviral agents that have potent activity against difficult-to-treat or resistant virus strains that threaten human health. Its product candidates are Tivoxavir marboxil, Ratutrelvir, and Narazaciclib. The company has four clinical programs: (i) tivoxavir marboxil, (ii) ratutrelvir, (iii) narazaciclib (ON 123300), and (iv) rigosertib. It is focused on the development of tivoxavir marboxil and ratutrelvir. The company derives revenue from its collaboration and licensing agreements.

Last trade $0.00
Day change $0.00 (0.00%)
Day range $0.24 – $0.275
Volume 110,710
Market cap $4M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$4M
Price / earnings
—
Price / book
2.36×
Price / sales
—
EV / sales
—
EV / EBITDA
0.05×

Profitability

Earnings per share
-$1.09
Return on assets
-145.91%
Return on equity
-989.71%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
0.93×
Quick ratio
0.93×
Cash ratio
0.52×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$19.43M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for TRAW, quarterly periods
Line itemQ2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024Q3 FY2024 Sep 30, 2024
Revenue$0$0$0$0$2.73M$57K$56K$57K
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$2.73M$57K$56K$57K
Selling, general and administrative$3.48M$2.03M$2.33M$1.74M$1.69M$2.75M$3.48M$3.48M
Research and development$1.1M$4.91M$5.04M$2.31M$2.29M$2.51M$1.86M$5.11M
Total operating expenses$3.18M$6.95M$7.37M$4.06M$3.98M$5.26M$5.33M$8.59M
Operating income-$3.18M-$6.95M-$7.37M-$4.06M-$1.25M-$5.2M-$5.28M-$8.54M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$3.05M-$7.11M-$7.44M-$3.96M-$915K$21.49M-$29.92M-$8.48M
Income taxes$0$0$0$0$0$0$0$0
Net income-$3.05M-$7.11M-$7.44M-$3.96M-$915K$21.49M-$29.92M-$8.48M
Net income attributable to common shareholders-$2.61M-$5.69M-$5.4M-$3.04M-$625K$15.08M-$21.42M-$1.43M
EBITDA-$3.13M-$6.9M-$7.32M-$4.04M-$1.25M-$5.2M-$5.28M-$8.53M
Basic earnings per share-$0.16-$0.53-$0.48-$0.34-$0.11$2.17-$6.31-$1.49
Diluted earnings per share-$0.16-$0.53-$0.46-$0.34-$0.11$2.09-$6.31-$1.49

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Traws Pharma Provides Regulatory Update on Influenza Program

Traws Pharma announced the deferral of its Phase 2a human influenza challenge study for tivoxavir marboxil (TXM) following a negative regulatory review by the UK's MHRA. While the compound showed potent efficacy in animal models, the company is advancing backup candidates with similar pharmacokinetic profiles while maintaining cash runway through Q1 2027.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Sep 23, 20241-for-25reverse split